Copyright
©The Author(s) 2019.
World J Clin Cases. Dec 26, 2019; 7(24): 4234-4244
Published online Dec 26, 2019. doi: 10.12998/wjcc.v7.i24.4234
Published online Dec 26, 2019. doi: 10.12998/wjcc.v7.i24.4234
Figure 2 Kaplan–Meier analyses of progression-free survival and overall survival in patients with multiple myeloma.
A: Overall survival of patients with multiple myeloma; B: Progression-free survival (PFS) of patients with multiple myeloma. The PFS rates at 2 and 3 years were 65.3% and 25.2%, respectively.
- Citation: Wang G, Ning FY, Wang JH, Yan HM, Kong HW, Zhang YT, Shen Q. Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance. World J Clin Cases 2019; 7(24): 4234-4244
- URL: https://www.wjgnet.com/2307-8960/full/v7/i24/4234.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i24.4234